19 March 2025 - Imugene is pleased to announce that the US FDA has granted fast track designation to its allogeneic CAR T-cell therapy azercabtagene zapreleucel for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Azercabtagene zapreleucel is an off the shelf, CD19 directed CAR T-cell therapy engineered to overcome the logistical challenges of autologous CAR T therapies, such as prolonged manufacturing times and limited patient access.